Loading
Tag every cell in a patient's lab-grown tumour with a unique DNA label, give it a drug, and read the labels to see which cells survive. This predicts which resistant clone will emerge.
Lentiviral cellular barcoding of organoids or PDX models allows quantitative clonal tracking under therapy. Applied to patient avatars before treatment, it would measure the pre-existing resistant clone fraction and fitness under candidate drugs, prioritising combinations that suppress all high-fitness clones rather than the bulk.
Shares Patient-derived xenografts, CRISPR functional genomics, Lab models that fail to predict what happens in patients.
Shares CRISPR functional genomics, Patient-derived organoids, Lab models that fail to predict what happens in patients, Tumour heterogeneity and clonal evolution.
Shares Patient-derived xenografts, CRISPR functional genomics, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares CRISPR functional genomics, Lab models that fail to predict what happens in patients, Drug resistance (primary and acquired).
Shares CRISPR functional genomics, Tumour heterogeneity and clonal evolution, Drug resistance (primary and acquired).
Shares Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Patient-derived xenografts, Patient-derived organoids.